Staar Surgical (STAA) reported $239M in revenue for fiscal 2025, −23.7% year on year. That ranks #2598 by revenue among 2853 SEC filers and #268 in Healthcare. It posted a net loss of −$80.4M for the same year. Revenue has grown 12.6% a year on average since 2016 ($82.4M then). The fiscal 2025 balance sheet shows $452M in total assets and $153M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $239M | −23.7% | FY20252026-01-02 |
| Gross profitGrossProfit | $182M | −23.9% | FY20252026-01-02 |
| Operating incomeOperatingIncomeLoss | −$91.7M | −$79.1M | FY20252026-01-02 |
| Net incomeNetIncomeLoss | −$80.4M | −$60.2M | FY20252026-01-02 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$34.2M | −$50.0M | FY20252026-01-02 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $5.8M | −75.1% | FY20252026-01-02 |
| Total assetsAssets | $452M | −11.4% | FY20252026-01-02 |
| Shareholders' equityStockholdersEquity | $344M | −13.4% | FY20252026-01-02 |
| CashCashAndCashEquivalentsAtCarryingValue | $153M | +6.2% | FY20252026-01-02 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-04-03 | $93.5M | $5.2M | Open → |
| Q2 20262026-07-03 | $93.5M | $8.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Staar Surgical Co
- Ticker
- STAA
- Exchange
- Nasdaq
- SIC classification
- Ophthalmic Goods (3851)
- Fiscal year end
- 01-02
- CIK
- 0000718937
Filings
- 10-QAug 12, 2026Open filing →
- 10-QMay 13, 2026Open filing →
- 10-KMar 3, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Lemaitre VascularLMAT | $250M | $57.7M |
| Arcus BiosciencesRCUS | $247M | −$353M |
| Keros TherapeuticsKROS | $244M | $87.0M |
| Staar SurgicalSTAA | $239M | −$80.4M |
| VaxartVXRT | $237M | $16,327 |
| OrthopediatricsKIDS | $236M | −$39.6M |
| Akebia TherapeuticsAKBA | $236M | −$5.3M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Staar Surgical — Key figures |url=https://companiesranked.com/en/company/staar-surgical |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Staar Surgical — Key figures. CompaniesRanked. https://companiesranked.com/en/company/staar-surgicalBibTeX
@misc{companiesranked-en-company-staar-surgical-2026,
author = {{CompaniesRanked}},
title = {{Staar Surgical — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/staar-surgical}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000718937-26-000004 · March 3, 2026
{{cite web |title=Staar Surgical — Key figures — 10-K (0000718937-26-000004) |url=https://www.sec.gov/Archives/edgar/data/718937/000071893726000004/staa-20260102.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.